People: Novo Nordisk A/S (NVO)

NVO on New York Consolidated

58.96USD
31 Jul 2015
Change (% chg)

$0.68 (+1.17%)
Prev Close
$58.28
Open
$59.33
Day's High
$59.35
Day's Low
$58.79
Volume
1,539,805
Avg. Vol
1,176,485
52-wk High
$59.49
52-wk Low
$41.72

Search Stocks

Summary

Name Age Since Current Position

Goran Ando

66 2013 Chairman of the Board

Kaare Schultz

53 2014 President, Chief Operating Officer

Lars Rebien Soerensen

60 2014 Chief Executive Officer

Jeppe Christiansen

55 2013 Vice Chairman of the Board

Jesper Brandgaard

51 2000 Chief Financial Officer, Executive Vice President

Lars Fruergaard Joergensen

48 2014 Executive Vice President of Corporate Development and Chief of Staff

Mads Krogsgaard Thomsen

54 2000 Chief Science Officer, Executive Vice President

Jakob Riis

48 2014 Executive Vice President of Marketing, Medical Affairs and Stakeholder Engagement

Sylvie Gregoire

54 2015 Director

Liselotte Hyveled

49 2014 Director, Employee Representative

Eivind Kolding

2015 Director

Anne Kverneland

58 2000 Director, Employee Representative

Stig Stroebaek

51 1998 Director, Employee Representative

Mary Szela

51 2015 Director

Soeren Thuesen Pedersen

50 2006 Director, Employee Representative

Bruno Angelici

68 2011 Independent Director

Liz Hewitt

58 2012 Independent Director

Thomas Koestler

64 2011 Independent Director

Kasper Roseeuw Poulsen

Head of Investor Relations, Corporate Vice President

Biographies

Name Description

Goran Ando

Dr. Goran A. Ando, M.D. has served as Chairman of the Board of Directors of Novo Nordisk A/S since March 20, 2013. He was Vice Chairman of the Company's Board from March 8, 2006 until March 20, 2013, and he has been Member of the Board of the Company since March 9, 2005. He has been Chairman of the Nomination Committee of the Company since April 2013. He was Chief Executive Officer (CEO) of Celltech Group plc in the United Kingdom until 2004. He joined Celltech from Pharmacia (currently Pfizer) where he was Executive Vice President and President of Research and Development with additional responsibilities for manufacturing, Information Technology, business development and Mergers & Acquisitions from 1995 to 2003. From 1989 to 1995, he was Medical Director, moving to Deputy Research and Development Director, and then Research and Development Director of Glaxo Group in the United Kingdom. He was also Member of the Glaxo Group Executive Committee. He is Specialist in General Medicine and Founding Fellow of the American College of Rheumatology in the United States. He serves as Chairman of the Board of Directors of Symphogen A/S and as Member of the Boards of Novo A/S, Molecular Partners AG and RAND Health. He also serves as Senior Advisor to Essex Woodlands Health Ventures Ltd. in the United Kingdom. He has qualifications and executive background within the international pharmaceutical industry. He qualified as Medical Doctor at Linkopings Universitet (the University of Linkoping) in 1973, and as Specialist in General Medicine at the same institution in 1978.

Kaare Schultz

Mr. Kaare Schultz has served as Chief Operating Officer (COO) and President of Novo Nordisk A/S since February 2014. Before that, he has been COO and Executive Vice President at the Company since March 2002. He joined the Company in 1989 as Economist in Health Care, Economy and Planning. In November 2000, he was appointed Chief of Staffs and Executive Vice President. He serves as Member of the Board of Directors at LEGO A/S and as Chairman of the Board of Directors at Royal Unibrew A/S. Mr. Schultz holds a Master of Science degree in Economics from Koebenhavns Universitet (the University of Copenhagen) from 1987.

Lars Rebien Soerensen

Mr. Lars Rebien Soerensen has served as Chief Executive Officer (CEO) at Novo Nordisk A/S since November 2000. He also served as President of the Company from November 2000 until January 30, 2014. He joined the Company's Enzymes Marketing in 1982. Over the years, he has been stationed in several countries, including the Middle East and the United States. He was appointed Member of Corporate Management in May 1994, and was given responsibility for Health Care within Corporate Management in December 1994. He is Member of the Boards of Directors of Thermo Fisher Scientific Inc. and Bertelsmann AG in Germany. He received the French award Chevalier de l'Ordre National de la Legion d'Honneur in 2005. Since October 2007, he has been Adjunct Professor at the Faculty of Life Sciences of Koebenhavns Universitet (the University of Copenhagen). He holds a Master of Science degree in Forestry from Koebenhavns Universitet from 1981 and a Bachelor of Science degree in International Economics from Copenhagen Business School from 1983.

Jeppe Christiansen

Mr. Jeppe Christiansen has been Vice Chairman of the Board of Directors of Novo Nordisk A/S since March 20, 2013. He is Chief Executive Officer of Fondsmaeglerselskabet Maj Invest A/S, Denmark, since 2009. He was Chief Executive Officer of LD Pensions from 2005 until 2009. Prior to that, he was Executive Director in Danske Bank from 1999 until 2004 with responsibility for group equity business and corporate international banking. From 1988 until 1999 he worked for LD Pensions, first as fund manager and later as deputy director with responsibility for the equity business. He is a Member of the Boards of Novo A/S, KIRKBI A/S, Symphogen A/S, as well as Vice Chairman of the Board of Haldor Topsoee A/S. He has background and experience within the financial sector, in particular in relation to financial and capital market issues, as well as insight into the investor perspective. He has a Master of Science in Economics from the University of Copenhagen (Koebenhavns universiteT), Denmark, from 1985.

Jesper Brandgaard

Mr. Jesper Brandgaard has served as Chief Financial Officer (CFO) and Executive Vice President at Novo Nordisk A/S since November 2000. He joined the Company in 1999 as Senior Vice President of Corporate Finance. He serves as Chairman of the Boards of Directors at SimCorp A/S and NNIT A/S, both in Denmark. He holds a Master of Science degree in Economics and Auditing from 1990, as well as a Master of Business Administration degree from 1995, both from the Copenhagen Business School in Denmark.

Lars Fruergaard Joergensen

Mr. Lars Fruergaard Joergensen has served as Executive Vice President of Corporate Development and Chief of Staff of Novo Nordisk A/S since November 24, 2014. He was Executive Vice President, Chief Information Officer of the Company from January 31, 2013 until November 24, 2014. He joined Novo Nordisk in 1991 as Economist in Health Care, Economy and Planning and has over the years completed overseas postings in the United States and Japan. In 2004, he was appointed Senior Vice President for IT (Information Technology) and Corporate Development. He is Chairman of the Board of NNE Pharmaplan A/S and Member of the Board of NNIT A/S, both in Denmark. He holds a Master of Science degree in Finance and Business Administration from Aarhus School of Business, Aarhus University (Aarhus Universitet), Denmark, from 1991.

Mads Krogsgaard Thomsen

Prof. Mads Krogsgaard Thomsen has served as Chief Science Officer (CSO) and Executive Vice President at Novo Nordisk A/S since November 2000. He joined the Company in 1991 and has been Head of Growth Hormone Research. He has been Head of Growth Hormone Research, Diabetes Research & Development, Global Drug Discovery. He has chaired Danish Research Council programs within endocrinology, and has served as President of the National Academy of Technical Sciences (ATV), Denmark. He sits on the Editorial Boards of international journals and is Member of the Board of Directors of University of Copenhagen, Denmark, as well as Chairman of the Board of Steno Diabetes Center A/S. He obtained a DMV degree in Veterinary Medicine from Koebenhavns Universitet in 1986, where he also obtained a Doctorate of Philosophy degree in 1989, and a Doctorate of Science degree in 1991. In 2000 he became Adjunct Professor of Pharmacology at the Royal Veterinary and Agricultural University (currently the Faculty of Health and Medical Sciences of the University of Copenhagen), Denmark.

Jakob Riis

Mr. Jakob Riis has served as Executive Vice President of Marketing, Medical Affairs and Stakeholder Engagement of Novo Nordisk A/S since November 24, 2014. He was Executive Vice President of Marketing & Medical Affairs of the Company from January 31, 2013 until November 24, 2014. He joined Novo Nordisk in 1996 as a health economist. From 2001 to 2005, he worked first in the United States sales force and then as Head of Marketing in Japan. In 2005, he was appointed Senior Vice President for International Marketing. He is also Chairman of the Board of Copenhagen Institute of Interaction Design and Member of the Board and Audit Committee of ALK-Abello A/S. He holds a Master of Science degree in Forestry from the Royal Veterinary and Agricultural University, Denmark (currently the Faculty of Science of the University of Copenhagen -Koebenhavns Univesitet) from 1992, where he also obtained a Doctorate of Philosophy degree in 1998.

Sylvie Gregoire

Ms. Sylvie L. Gregoire is Director of Novo Nordisk A/S. Ms. Grégoire is former president of Human Genetic Therapies Shire PLC, US and Switzerland, from 2007 to 2013. The Board of Directors recommends election of Ms Grégoire primarily because of her deep knowledge of the regulatory environment in both the US and the EU having experience with all phases of the product life cycle from discovery, registration, pre-launch and managing the life cycle while on the market. In addition, Sylvie Grégoire has financial insight from i.a. P&L responsibility.

Liselotte Hyveled

Ms. Liselotte Hyveled has been Director, Employee Representative at NOVO NORDISK A/S since February 27, 2014. She is project vice president for Novo Nordisk’s prandial insulin projects Faster-acting insulin aspart and Prandial BioEdge in Insulin, GH & Devices in Global Development. She holds Master of Science (1992) from Copenhagen University, and Master of Medical Business Strategies (2011) from Copenhagen Business School, both in Denmark.

Eivind Kolding

Mr. Eivind Kolding is Director of Novo Nordisk A/S. Mr. Kolding is chief executive officer of Novo A/S, Denmark. The Board of Directors recommends election of Mr. Kolding primarily because of his extensive executive experience in large multinational companies headquartered in Denmark within regulated markets and his significant financial knowledge.

Anne Kverneland

Ms. Anne Marie Kverneland has been Employee Representative on the Board of Directors at Novo Nordisk A/S since November 2000. She has been Member of the Novo Nordisk Foundation since 2014. She joined the Company in July 1981 as Laboratory Technician and is currently working as Shop Steward. She has a degree in Medical Laboratory Technology from Koebenhavns Universitet (Copenhagen University Hospital) in Denmark from 1980.

Stig Stroebaek

Mr. Stig Stroebaek has been Employee Representative on the Board of Directors at Novo Nordisk A/S since 1998. He has been Member of the Audit Committee of the Company since April 2013. He joined the Company in 1992 as Electrician and is Shop Steward in the Company. Mr. Stroebaek holds a diploma in Electrical Engineering and a diploma in further training for Members of the Boards of Directors from the Danish Employees’ Capital Pension Fund (LD) from 2003.

Mary Szela

Ms. Mary T. Szela is Director of Novo Nordisk A/S. Ms. Szela is chief executive officer of Melinta Therapeutics, Inc., US. The Board of Directors recommends election of Ms. Szela primarily because of her deep understanding of the clinical, regulatory and marketing aspects of the pharmaceutical industry in North America having both operational and strategic experience.

Soeren Thuesen Pedersen

Mr. Soeren Thuesen Pedersen has been Employee Representative on the Board of Directors at Novo Nordisk A/S since March 2006. He joined the Company in January 1994. He works as External Affairs Director in Quality Intelligence in the Company. He is Member of the Boards of HOFOR A/S, HOFOR Forsyning Holding PS, HOFOR Forsyning omplementar A/S and HOFOR FOrsyning A/S. He graduated with a Bachelor of Science degree in Chemical Engineering from Danmarks Ingenioerakademi, currently part of Danmarks Tekniske Univeristet, in 1988.

Bruno Angelici

Mr. Bruno F. J. Angelici has served as Independent Member of the Board of Directors of Novo Nordisk A/S since March 23, 2011. He has been Member of the Nomination Committee of the Company since April 2013. He was Executive Vice President of AstraZeneca, with P&L responsibility for Europe, Japan, Asia Pacific, Latin America, Middle East and Africa from 2001 until 2009. In 1998, he was appointed President of Zeneca, Japan. Previously, from 1989, he was President of Zeneca, France, having joined from Baxter International, where he held various management positions from 1978 to 1989. He is Member of the Board of Directors of Smiths Group plc and Wolters Kluwer, as well as Chairman of the Board of Vectura Group plc. Additionally, he is Member of the Global Advisory Board at Takeda Pharmaceutical Company Limited, Japan. He has global experience with two companies in the fields of pharmaceuticals and medical devices, as well as knowledge of strategy, sales, marketing and governance of main companies. He holds a Bachelor of Arts degree in Business Administration from Ecole Superieure de Commerce Reims from 1971. He graduated in Law from Universite de Reims Champagne Ardenne in 1973. In addition, he has a Master of Business Administration degree from Kellogg School of Management at NorthWestern University from 1978 and an AMP from Harvard Business School from 1993, both in the United States.

Liz Hewitt

Ms. Liz Hewitt has been Independent Member of the Board of Directors of Novo Nordisk A/S since March 21, 2012. She has been Member of the Company's Audit Committee since March 2012 and Member of the Nomination Committee since April 2013. She was previously Group Director Corporate Affairs for Smith & Nephew plc from 2004 until 2011 and was involved at a senior level in all aspects of the business, including membership of Risk Committee of the company. From 1986 until 2004, she held a number of roles at 3i Group plc, from investing and syndicating private equity transactions to running the internal consultancy team, culminating her role as Director Corporate Affairs, when she was a Member of Risk Committee and a Trustee of the 3i Charitable Foundation. She qualified with Andersen & Co and also worked as a private equity investor for Citicorp Venture Capital (currently CVC) and Gartmore Investment Management Ltd. She serves as Member of the Board of Melrose Industries plc and Savilles plc. She is also External Member of the Audit Committee of the House of Lords, the United Kingdom. She has experience within the field of medical devices, financial knowledge and knowledge of how international companies operate. She holds a Bachelor of Science degree with honors in Economics from University College London from 1977 and became Chartered Accountant FCA from the Institute of Chartered Accountants in 1982.

Thomas Koestler

Dr. Thomas (Tom) Paul Koestler, Ph.D. has served as Independent Member of the Board of Directors of Novo Nordisk A/S since March 23, 2011. He is an Executive with Vatera Holdings LLC, the United States. From 2003 to 2009, he was Executive Vice President, and from 2006 President of Schering-Plough Research Institute. Before joining Schering-Plough Research Institute, he was Senior Vice President and Global Head of Regulatory Affairs of Pharmacia Corporation, from 2001. From 1996 to 2001, he was Vice President, later Senior Vice President in Novartis Pharmaceuticals within Regulatory Affairs. From 1982 to 1996, he held various management positions within Regulatory Affairs and Clinical Safety in Sandoz Pharmaceutical Corporation, Johnson & Johnson Bristol-Myers Squibb, and Smith Kline French Labs. He is Chairman of the Board of Melinta Therapeutics Inc. and Member of the Board of Directors of Momenta Pharmaceuticals Inc., ImmusanT Inc., Edgemont Pharmaceuticals LLC and Arisaph Pharmaceuticals Inc. He has Research and Development knowledge, both generally and within the field of regulatory affairs. He has know-how about the pharmaceutical industry in general and how international corporations operate. He has additional knowledge of the United States market. He holds a Bachelor of Science degree in Biology from Daemen College from 1975, and a Doctorate of Philosophy degree in Medicine and Pathology from the Roswell Park Memorial Institute, part of State University of New York, from 1982.

Kasper Roseeuw Poulsen

Basic Compensation

Search Stocks